SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin

Código QR

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin

Jochen SeufertDepartment of Endocrinology and Diabetology, Clinic for Internal Medicine II, Freiburg University Hospital, Freiburg, GermanyAbstract: Despite the availability of a great variety of medications, a significant proportion of people with type 2 diabetes mellitus (T2DM) are not able to ach...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Seufert J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9f52342de08b43dc8e1d4bbbeae9ffa2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser RF, et al.
Publicado: (2013)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming JW, et al.
Publicado: (2015)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019)

Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors
por: Braha A, et al.
Publicado: (2019)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice
por: David-Silva A, et al.
Publicado: (2020)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)

The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
por: Gerlanc NM, et al.
Publicado: (2017)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley JM, et al.
Publicado: (2012)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
por: Katrine B Hansen, et al.
Publicado: (2010)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora BM, et al.
Publicado: (2020)

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
por: Gharaibeh NE, et al.
Publicado: (2019)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017)

Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications
por: Wondmkun YT
Publicado: (2020)

Sex differences in type 2 diabetes: focus on disease course and outcomes
por: Arnetz L, et al.
Publicado: (2014)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Stanley S Schwartz
Publicado: (2010)

Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes
por: Mackenzie RWA, et al.
Publicado: (2014)

AMPK activation: a therapeutic target for type 2 diabetes?
por: Coughlan KA, et al.
Publicado: (2014)

Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy
por: Amy Fleischman, et al.
Publicado: (2009)

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
por: Thuillier P, et al.
Publicado: (2015)

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
por: Kumiko Shiba, et al.
Publicado: (2018)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
por: Kim Y, et al.
Publicado: (2012)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo E, et al.
Publicado: (2013)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
por: Takahara M, et al.
Publicado: (2020)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Gregory E Peterson
Publicado: (2009)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia N
Publicado: (2011)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
por: Wilke T, et al.
Publicado: (2019)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010)

Insulin glulisine in the management of diabetes
por: Satoru Yamada
Publicado: (2009)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Paul Valensi
Publicado: (2009)

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients
por: Scheen AJ
Publicado: (2020)

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
por: Jiang YK, et al.
Publicado: (2019)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)